BPMC — Blueprint Medicines Income Statement
0.000.00%
Last trade - 00:00- $5.66bn
- $5.43bn
- $508.82m
- 37
- 14
- 47
- 24
Annual income statement for Blueprint Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 794 | 180 | 204 | 249 | 509 |
| Cost of Revenue | |||||
| Gross Profit | 793 | 162 | 186 | 241 | 489 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 485 | 822 | 742 | 736 | 547 |
| Operating Profit | 309 | -642 | -538 | -486 | -38.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 315 | -641 | -552 | -506 | -65.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 314 | -644 | -558 | -507 | -67.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 314 | -644 | -558 | -507 | -67.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 314 | -644 | -558 | -507 | -67.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5.59 | -11 | -9.35 | -8.37 | -2.86 |